Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.

Authors: Elena Elez, Popova Natalia, Grant McCarthy, Rachid Massaad, David R. Fogelman, Ruixuan Jiang, Dung T. Le

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.3631

Source: Full article

3631